• Guidance in managing pre-existing heart disease during cancer treatment
• Prevention , early detection and management of cardiotoxicity that may occur from a wide range of cancer treatments , including chemotherapy , targeted therapy , immunotherapy , cellular therapy , and radiation therapy
• Preventive care and cardiac monitoring for those at risk of long-term cardiotoxicity in survivorship , including patients with exposure to radiation , hormone therapy , bone marrow transplants , and certain chemotherapies
• Cardioprotective treatment
• Cardiotoxicity risk assessment
• Cardiovascular risk factor optimization
• Cardiac biomarker monitoring
• Advanced multi-modality cardiac imaging surveillance
• Blood stem cell transplant
• Chemotherapy
• Clinical trials
• Kidney transplant
• Liver transplant
• Medication
17
Cardio-Oncology Center
In addition to traditional chemotherapy , novel cancer therapies have a wide range of potential cardiotoxicity during and after cancer treatment , including hypertension , heart rhythm disorders , obstructive coronary artery disease , and cardiomyopathies or weakened heart muscle .
Through a collaborative approach with oncologists , cardiologists and other providers , the Cardio- Oncology Center at Baylor Scott & White Heart and Vascular Hospital — Dallas is committed to individualized care throughout the cancer spectrum , including :
• Guidance in managing pre-existing heart disease during cancer treatment
• Prevention , early detection and management of cardiotoxicity that may occur from a wide range of cancer treatments , including chemotherapy , targeted therapy , immunotherapy , cellular therapy , and radiation therapy
• Preventive care and cardiac monitoring for those at risk of long-term cardiotoxicity in survivorship , including patients with exposure to radiation , hormone therapy , bone marrow transplants , and certain chemotherapies
Courtney M . Campbell , MD , PhD , FACC - Medical Director
Led by the center ’ s medical director and board-certified cardio-oncologist , Courtney M . Campbell , MD , PhD , FACC , the team works closely with providers and their patients . Coordinated by a nurse navigator , patients benefit from the combined power of expertise in two disciplines — cardiology and oncology — with proven approaches .
Ongoing surveillance and diagnostics
Cardio-oncology evaluations include individually customized , comprehensive monitoring plans with :
• Cardioprotective treatment
• Cardiotoxicity risk assessment
• Cardiovascular risk factor optimization
• Cardiac biomarker monitoring
• Advanced multi-modality cardiac imaging surveillance
Amyloidosis program
The amyloidosis program in Dallas offers a customized plan of care for primary amyloidosis and hereditary amyloidosis led by a multidisciplinary team of specialists , including advanced heart failure and transplant cardiologists and a cardio-oncologist . Advanced treatment options include :
• Blood stem cell transplant
• Chemotherapy
• Clinical trials
• Kidney transplant
• Liver transplant
• Medication
3
Related publications
Enroller nationwide
Helios-A Principal investigator : Parag Kale , MD , FACC , FHFSA
Campbell CM , Baiyee CAMT , Almaani S , Bumma N , Sharma N , LoRusso S , Redder E , Bittengle J , Pfund K , Friemer M , Tong M , Kahwash R , Efebera Y , Parikh S , Vallakati A . Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy . American Journal of Therapeutics . 2023 September / October 01 ; 30 ( 5 ): e447-e453 .
Cheng R , Kittleson MM , Wechalekar AD , Alvarez- Cardona J , Mitchell JD , Scarlatelli Macedo AV , Dutra JPP , Campbell CM , Liu JE , Landau HJ , Davis MK , Morrissey S , Casselli S , Lousada I , Seabra-Garcez JD , Szor RS , Ganatra S , Trachtenberg B , Maurer MS , Stockerl-Goldstein K , Lenihan D . Moving towards establishing centres of excellence in cardiac amyloidosis : an International Cardio-Oncology Society statement . Heart British Cardiac Society . 2024 January 24 : heartjnl-2023-323502 .
Garcia-Pavia P , Grogan M , Kale P , Berk JL , Maurer MS , Conceição I , Di Carli M , Solomon SD , Chen C , Yureneva E , Vest J , Gillmore JD . Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy . European Journal of Heart Failure . 2024 February 6 .
Contact the center : 214.820.7162 CardioOncologyCenter @ BSWHealth . org
Baylor Scott & White Heart and Vascular Hospital — Dallas | Advanced Cardiovascular Centers